Zelira Therapeutics Ltd. (AU:ZLD) has released an update.
Zelira Therapeutics Ltd., a leader in developing clinically validated cannabis medicines, has received a $919,000 cash refund from the Australian Federal Government’s R&D Tax Incentive Scheme. The funds will bolster working capital, aiding the progression of Zelira’s clinical development programs and business operations. The company is advancing its proprietary treatments, including a novel cannabinoid-based medicine, and is expanding its commercial presence internationally.
For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.
